To evaluate if increasing CX43 channel accretion into gap junction plaque affects prostate cancer cell growth, we utilized the ACT-1 (alpha connexin 43 carboxy-terminus peptide 1), a 25 mer synthetic cell membrane permeable peptide derived from Cx43 that specifically targets the interaction between Cx43 and zonula occuludens (ZO)-1 and releases the inhibition of ZO-1 on the structural organization of Cx43 gap junctions [18]. Here, TJP1 is linked to Familial prostate cancer.